Built to Make Waves

Michael Onuscheck joined Presidio Medical in September 2021 as CEO and Chairman, after serving more than two years as an independent member of Presidio’s board. He has decades of experience in the medical device industry. Previously, he served on the Executive Committee of Alcon and as President, Global Businesses & Innovation. He also led Alcon’s Surgical Products business as President & General Manager, helping to turn around and then spin Alcon out of Novartis. Prior to Alcon, Michael held positions at Boston Scientific (President of EMEA and Russia, and Senior Vice President and President of the Neuromodulation Division), and in a variety of commercial roles at Medtronic Sofamor Danek, and Pfizer.

Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College.

Valerie Cimmarusti joined Presidio Medical in February 2022 as the Senior Vice President of Regulatory, Quality & Clinical. She has over 25 years of global experience in Regulatory, Quality Assurance/Quality Control, Global Compliance, and Clinical. Valerie has worked with Class III Implantable Medical Devices, Class II & I Devices, In-Vitro Diagnostics, Pharma & Biotech Industries. Previously, she held roles at Boston Scientific, St. Jude Medical, Quest Diagnostics and Baxter Healthcare.

Valerie received a B.S. in Microbiology with a minor in Chemistry from Cal Poly Pomona and obtained a Regulatory Affairs Certification (RAC).

Mark Murray joined Presidio Medical in July 2020 as CFO (consulting). He has more than 40 years of experience in Medtech, Biotech and Diagnostics in both the public and private sector. Mark spent 21 years with Guidant Corporation, where he was part of the senior management team and participated in its $1 billion IPO through its acquisition by Boston Scientific and Abbott for $27 billion. After Guidant, Mark served as CFO for several companies including OptiMedica, Oculeve, ClarVista, Kedalion Therapeutics and Oyster Point Pharma. Mark currently serves as a partner at FLG Partners LLC.

Mark received his B.S. in business administration from San Francisco State University.

Katherine Neuenfeldt joined Presidio Medical in April 2021 as the Senior Vice President of Commercial Strategies. She has 20 years of experience in commercializing implantable medical devices. Prior to Presidio, she was the Vice President of Market Access at Nevro, where she led the Market Access and Marketing functions as they grew from a small, private company to an established player. She also led multiple high-profile product launches at Medtronic Endovascular and held roles at Johnson & Johnson, HealthTech, and Triage Consulting Group.

Katherine received a B.A. in Human Biology from Stanford University, an M.S. in Epidemiology and Clinical Research from the Stanford School of Medicine, and an M.B.A. from the Darden School of Business at the University of Virginia.

Thomas Nyikos joined Presidio Medical in January 2024 as the Vice President of Product Development. He has over 18 years of experience in medical device engineering, product development and project management roles, and has launched multiple Class III products. At Presidio, Thomas is responsible for all aspects of product development and scientific research. Previously, he held leadership roles at Thoratec and St. Jude Medical. After Abbott acquired St. Jude Medical, he spent 7 years at Abbott as Director of R&D for the Mechanical Circulatory Support business, where he was in charge of teams in the US and Switzerland.

He received his B.S. and M.S. in Electrical Engineering and Information Technology from ETH Zurich and an M.B.A. from the University of Southern Queensland.

Scott Salys joined Presidio Medical in January 2023 as the Chief Research & Development and Operations Officer. He has over 25 years of experience in Class III active implantable devices, leading R&D, Operations, Supply Chain, Program Management, and Durable Medical Equipment organizations. Before joining Presidio, he was the Divisional Vice President of R&D and Divisional Vice President of Operations at Abbott’s Heart Failure business, which he led through rapid growth and expansion. Prior to Abbott (through its acquisition of St. Jude Medical), he spent more than 16 years at SJM in various R&D, Operations, and Supply Chain roles.

Scott received his B.S. in Bioengineering from Texas A&M University and holds 13 patents.

Andrew joined Presidio in 2017 and has since served as the Chief Medical Officer. At Presidio, he has conducted preclinical safety studies, human clinical research, collaborated cross-functionally to ensure the quality and safety of our technology, and has worked extensively with our physician partners.  He has over a decade of experience in both the medical device industry as a consultant and executive as well as a board-certified anesthesiologist.  Andrew’s professional interests include first-in-human clinical research, proof of concept translational science, early-stage start-up product market fit assessments and physician entrepreneurship. 

He completed his medical training at Indiana University and his residency at the University of Colorado in Anesthesiology.

Angie Yi joined Presidio Medical in January 2024 as the Senior Director of Human Resources. She leads all aspects of the HR function for the company, including Talent Attraction, Talent Development, Total Rewards, HR Operations and the HRBP function. She has more than 20 years of broad-based human resources experience in the high-tech, fintech and the life science industries. She spent the first 10 years of her career at Microsoft in multiple roles, including talent attraction, HR operations, and mergers and acquisitions support. Angie has worked in multiple senior roles, partnering with executive teams to develop and execute business-aligned HR strategies. She has had leadership roles at Pear Therapeutics, Model N, Inc. and most recently at Amyris.

Angie received her B.S in Visual Communications from the University of California, Davis.

Michael Ackermann is co-founder and a board member of Presidio Medical. Michael is also co-founder and Chairman of Tarsus Pharmaceuticals (NASDAQ: TARS), and teaching faculty at the Stanford University Byers Center for Biodesign. Previous roles included co-founder and Chairman of Oyster Point Pharma (NASDAQ: OYST), Vice President, Neurostimulation for Allergan, plc and co-founder and CEO of Oculeve, Inc., which was acquired by Allergan.

He received a B.E. degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, and is a graduate of the Biodesign and Vision Research Fellowships at Stanford University. He has numerous patents and peer-reviewed publications.

Rick is the Chief Financial Officer (CFO) of Inspire Medical Systems, a publicly traded medical device company dedicating to redefining the standard of care for obstructive sleep apnea and has served in that role since May 2014. From 2006 to 2013, he was the CFO, Secretary, and Treasurer at superDimension, Ltd., a medical device manufacturer acquired by Covidien in 2012. He has also served as the CFO of Vascular Solutions.

Rick began his career at Ernst and Young, where he worked with multiple public and private medical technology firms. He holds a B.B.A. from the University of Wisconsin, Eau Claire and is a Certified Public Accountant (inactive).

Juan-Pablo is a partner at Action Potential Venture Capital based in Palo Alto, CA, and invests in start-ups that are pioneering bioelectronic medicines. He is a Board member of various companies developing therapies that leverage “electricity as medicine,” a promising alternative to traditional drug therapies. He was previously a medical device investor at Lightstone Ventures and Morgenthaler Ventures. Prior to investing, Juan-Pablo led efforts across R&D and Strategy in Medtronic’s CardioVascular Division, and subsequently served on the CV Global Brand Strategy team at Eli Lilly.

Juan-Pablo earned an MBA from Stanford Graduate School of Business, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford’s Neuroscience Institute (Wu Tsai), the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC.

David Neustaedter, Ph.D., is a Venture Partner on the Medical Technologies team at Deerfield Management and joined the Firm in 2022. Prior to Deerfield, Dr. Neustaedter spent seven years as a Vice President, at Medtronic Ventures and, before Medtronic’s merger with Covidien, spent a further 7 years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght, and Braun Consulting.

Dr. Neustaedter holds a B.Sc. in Cellular, Molecular, and Microbial Biology from University of Calgary, an M.B.A from Yale University, and a Ph.D. in Molecular Biology from University of British Columbia.

Ben is a partner at Invus Opportunities, a New York based investment firm that currently manages over $1.5 billion of capital. Ben joined Invus Opportunities in 2008 when the firm spun off from sister firm The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben leads investments by Invus Opportunities in growing private companies and works in close partnership with market-leading management teams and investors to create lasting value. Ben has served on the Board of Directors of numerous companies, both in the healthcare sector as well as in other industries. Prior to joining Invus Opportunities, Ben was a management consultant at the Monitor Group.

Ben received a B.S. in business administration from the University of Southern California and an M.B.A. from Harvard Business School.

Kenneth is a co-founder of Presidio Medical and previously served as President & CTO. Before Presidio, he was COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes.Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P.

He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.